News AZ, Daiichi get Datroway nod in lung cancer on second try AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.
News ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer.
News MSD and Daiichi Sankyo pull HER3-DXd's FDA filing MSD and Daiichi Sankyo suffer another setback with their HER3 programme ahead of a crucial data readout at ASCO.
News New data could move Enhertu into early breast cancer AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.
News Enhertu poised to move first line in HER2+ breast cancer New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.
News AZ, Daiichi get EU okay for breast cancer drug Datroway AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for Datroway, their TROP2-directed ADC for breast cancer.
